Neuroscience Catalyst to Focus on Mood Disorders and Alzheimer’s Disease
Janssen Inc. (Janssen) today announced it has signed an agreement, facilitated by the Johnson & Johnson Innovation center in California, with the University of Toronto’s Centre for Collaborative Drug Research (CCDR) to form an open-source collaboration focused on novel therapeutic approaches to the treatment and management of mood disorders and Alzheimer’s disease.
{iframe}http://www.marketwatch.com/story/janssen-inc-and-johnson-johnson-innovation-establish-research-collaboration-with-the-university-of-toronto-2014-09-08{/iframe}